Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "Revaxis" (44)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
(Codice) 42 products
WHO-DDD
IP
Tapentadol Sandoz Retard 150 mg
30
48.28
68.90
10 %
Delayed release tablets: Tapentadolum 150 mg
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Tapentadol Sandoz Retard 150 mg
60
84.98
108.85
10 %
Delayed release tablets: Tapentadolum 150 mg
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
CM
Ibuprofen Viatris 400 mg
20
1.56
10.95
10 %
Coated tablets: Ibuprofenum 400 mg
Viatris Pharma GmbH
B / SL / SG
FB
G
IP
CM
Ibuprofen Viatris 400 mg
50
3.37
12.90
10 %
Coated tablets: Ibuprofenum 400 mg
Viatris Pharma GmbH
B / SL / SG
FB
G
L
IP
Lisdexamfetamin Spirig HC 40 mg
30
46.64
67.15
10 %
Capsules: Lisdexamfetamini Dimesilas 40 mg
Spirig HealthCare AG
A+ / SL / SG
FB
G
L
IP
V/S
Engerix-B 20
23.66
42.15
10 %
Injection suspension: Hepatitidis b viri Antigenum Adnr 20 µg/ml
GlaxoSmithKline AG
B / SL
FB
G
L
IP
Ruxience 500 mg/50 ml
1051.32
1159.80
10 %
Concentrate for infusion: Rituximabum 500mg / 50ml
Pfizer AG
A / SL
FB
G
IP
CI
Casgevy 4-13 x 10e6
cells/ml
PR
PR
k.A.
Vertex
Pharmaceuticals (CH)
GmbH
A
FB
G
IP
CI
Ebvallo
PR
PR
k.A.
Pierre Fabre Pharma SA
A
FB
G
IP
V/S
Engerix-B 20
10
PR
PR
k.A.
Injection suspension: Hepatitidis b viri Antigenum Adnr 20 µg/ml
GlaxoSmithKline AG
B
FB
G
IP
Xenpozyme 4 mg
PR
PR
k.A.
poudre pour solution à diluer pour perfusion: Olipudasum Alfa 4 mg
Sanofi-Aventis
(Suisse) SA
A
FB
G
IP
Xenpozyme 4 mg
10
PR
PR
k.A.
poudre pour solution à diluer pour perfusion: Olipudasum Alfa 4 mg
Sanofi-Aventis
(Suisse) SA
A
FB
G
IP
Xenpozyme 20 mg
PR
PR
k.A.
poudre pour solution à diluer pour perfusion: Olipudasum Alfa 20 mg
Sanofi-Aventis
(Suisse) SA
A
FB
G
IP
Xenpozyme 20 mg
10
PR
PR
k.A.
poudre pour solution à diluer pour perfusion: Olipudasum Alfa 20 mg
Sanofi-Aventis
(Suisse) SA
A
FB
G
L
IP
CI
Emtricitabin-Tenofovir-
Mepha
30
42.33
72.00
10 %
Coated tablets: 2 Active Agents
Mepha Pharma AG
●
A / SL / SG
FB
G
L
IP
CI
Emtricitabin-Tenofovir-
Mepha
30
42.33
72.00
10 %
Coated tablets: 2 Active Agents
Mepha Pharma AG
●
A / SL / SG
FB
G
L
IP
CI
Rivaroxaban-Mepha 10 mg
14
9.40
19.35
10 %
Coated tablets: Rivaroxabanum 10 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
CI
Rivaroxaban-Mepha 10 mg
28
18.81
36.95
10 %
Coated tablets: Rivaroxabanum 10 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
CI
Rivaroxaban-Mepha 10 mg
98
69.13
91.65
10 %
Coated tablets: Rivaroxabanum 10 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
CI
Rivaroxaban-Mepha 10 mg
100
70.54
93.10
10 %
Coated tablets: Rivaroxabanum 10 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Binocrit 8000 IE/0,8 ml
6 x 0.8 ml
297.96
340.45
10 %
Injection solution in prefilled syringe: Epoetinum Alfa 8000U.I. / 0.8ml
Sandoz
Pharmaceuticals AG
A / SL
FB
G
L
IP
CI
Enbrel 25 mg
Set(s)
405.49
455.15
10 %
Lyophilisate and solvent: Etanerceptum 25 mg
Pfizer AG
B / SL
FB
G
IP
Moviprep Orange
2 Sachet(s)
11.51
28.95
10 %
Soluble Powder: 4 Active Agents
Soluble Powder: 2 Active Agents
Norgine AG
B / SL
FB
G
L
IP
Bavencio 200 mg/10 ml
827.76
916.65
10 %
Concentrate for infusion: Avelumabum 200mg / 10ml
Merck (Schweiz) AG
A / SL
FB
G
L
IP
Bavencio 200 mg/10 ml
4
3311.04
3617.35
10 %
Concentrate for infusion: Avelumabum 200mg / 10ml
Merck (Schweiz) AG
A / SL
FB
G
L
IP
Vegzelma 100 mg/4 ml
257.57
296.55
10 %
Concentrate for infusion: Bevacizumabum 100mg / 4ml
iQone Healthcare
Switzerland SA
A / SL
FB
G
L
IP
Vegzelma 400 mg/16 ml
962.84
1063.55
10 %
Concentrate for infusion: Bevacizumabum 400mg / 16ml
iQone Healthcare
Switzerland SA
A / SL
FB
G
L
IP
PP
Herceptin subkutan
600mg/5ml
1484.04
1630.40
10 %
Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
L
IP
Ogivri 150 mg
456.84
513.25
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg
Medius AG
A / SL
FB
G
IP
CI
Bilaxten 6 mg / ml
5 ml
PR
PR
k.A.
Eye drops: Bilastinum 6 mg/ml
A. Menarini GmbH
B
FB
G
IP
CI
Aspégic 100
20 Sachet(s)
PR
PR
k.A.
Soluble Powder: DL-Lysini Acetylsalicylas 180 mg
Opella Healthcare
Switzerland AG
D
FB
G
IP
CI
Aspégic 100
100 Sachet(s)
PR
PR
k.A.
Soluble Powder: DL-Lysini Acetylsalicylas 180 mg
Opella Healthcare
Switzerland AG
B
FB
G
IP
CI
Aspégic 500
20 Sachet(s)
PR
PR
k.A.
Soluble Powder: DL-Lysini Acetylsalicylas 900 mg
Opella Healthcare
Switzerland AG
D
FB
G
IP
CI
Ph
Bronchostop Duo
Hustensaft
120 ml
PR
PR
k.A.
Solution (oral): 2 Active Agents
Hänseler AG
D
FB
G
IP
CI
Ph
Bronchostop Duo
Hustensaft
200 ml
PR
PR
k.A.
Solution (oral): 2 Active Agents
Hänseler AG
D
FB
G
IP
V/S
VeraSeal 2 ml
2 x 1 ml
PR
PR
k.A.
Lösung für Gewebekleber: Fibrinogenum Humanum 80 mg/ml
Lösung für Gewebekleber: Thrombinum Humanum 500 UI/ml
Janssen-Cilag AG
B
FB
G
IP
V/S
VeraSeal 4 ml
2 x 2 ml
PR
PR
k.A.
Lösung für Gewebekleber: Fibrinogenum Humanum 160mg / 2ml
Lösung für Gewebekleber: Thrombinum Humanum 1000U.I. / 2ml
Janssen-Cilag AG
B
FB
G
IP
V/S
VeraSeal 6 ml
2 x 3 ml
PR
PR
k.A.
Lösung für Gewebekleber: Fibrinogenum Humanum 240mg / 3ml
Lösung für Gewebekleber: Thrombinum Humanum 1500U.I. / 3ml
Janssen-Cilag AG
B
FB
G
IP
V/S
VeraSeal 10 ml
2 x 5 ml
PR
PR
k.A.
Lösung für Gewebekleber: Fibrinogenum Humanum 400mg / 5ml
Lösung für Gewebekleber: Thrombinum Humanum 2500U.I. / 5ml
Janssen-Cilag AG
B
FB
G
IP
Mylotarg 5 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg
Pfizer AG
A
FB
G
IP
Padcev 20 mg
681.24
798.45
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Enfortumabum Vedotinum 20 mg
Astellas Pharma AG
A
FB
G
IP
Padcev 30 mg
1028.09
1189.05
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Enfortumabum Vedotinum 30 mg
Astellas Pharma AG
A
FB
G
Diphtheria-Poliomyelitis-Tetanus (J07CA01) 2 products
WHO-DDD
DrugBank.ca
IP
V/S
Revaxis
PR
PR
k.A.
Injection suspension: 2 Active Agents
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
V/S
Revaxis
10
PR
PR
k.A.
Injection suspension: 2 Active Agents
Sanofi-Aventis
(Suisse) SA
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
